Plain-English translation of NCT07712679 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging technology called FAPI PET/CT to detect and measure scarring (fibrosis) in kidneys. Right now, doctors often need to perform a kidney biopsy — an invasive procedure with risks of bleeding — to see how much damage has occurred. This study is exploring whether the imaging scan can show the same information safely and without surgery.
Kidney biopsies carry real risks, including bleeding that sometimes requires transfusions or additional procedures. Many patients with chronic kidney disease also take blood thinners, which means they'd have to stop these protective medications before a biopsy — creating a gap in their care. Doctors need a safer, non-invasive way to see what's happening inside the kidney.
You likely qualify if…
You likely don't qualify if…
You will undergo a FAPI PET/CT scan, a specialized imaging test that takes pictures of your kidney to detect scarring. The scan is non-invasive and does not require surgery, biopsies, or stopping your medications. The study will enroll about 30 people at the Medical University of Vienna.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Austria
Medical University of Vienna
Enrollment target
~30 participants
Started
September 2025
Primary completion
September 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Constantin N Aschauer, MD
Medical University of Vienna, Internal Medicine III, Department of Nephrology and Dialysis
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.